MA49513A - Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines - Google Patents

Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines

Info

Publication number: MA49513A
Authority: MA; Morocco
Prior art keywords: recombinated; tropism; modified; viral vectors; human cells
Prior art date: 2017-06-27

Application number

MA049513A

Other languages

English (en)

Other versions

MA49513B1 (fr

Inventor

Christos Kyratsous

Andrew J Murphy

Leah Sabin

Cheng Wang

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-27

Filing date

2018-06-27

Publication date

2020-05-06

2018-06-27 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2020-05-06 Publication of MA49513A publication Critical patent/MA49513A/fr

2024-05-31 Publication of MA49513B1 publication Critical patent/MA49513B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA49513A 2017-06-27 2018-06-27 Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines MA49513B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762525704P	2017-06-27	2017-06-27
PCT/US2018/039874 WO2019006043A1 (fr)	2017-06-27	2018-06-27	Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines

Publications (2)

Publication Number	Publication Date
MA49513A true MA49513A (fr)	2020-05-06
MA49513B1 MA49513B1 (fr)	2024-05-31

Family

ID=63080487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA49513A MA49513B1 (fr)	2017-06-27	2018-06-27	Vecteurs viraux recombinants au tropisme modifié et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines

Country Status (29)

Country	Link
US (1)	US20200140491A1 (fr)
EP (2)	EP4372008A3 (fr)
JP (4)	JP7372154B2 (fr)
KR (3)	KR102877478B1 (fr)
CN (2)	CN110799524A (fr)
AU (3)	AU2018290882B2 (fr)
BR (1)	BR112019027854A2 (fr)
CA (1)	CA3066947A1 (fr)
CL (3)	CL2019003842A1 (fr)
CO (1)	CO2019014683A2 (fr)
DK (1)	DK3645551T5 (fr)
ES (1)	ES2978295T3 (fr)
FI (1)	FI3645551T3 (fr)
HR (1)	HRP20240773T1 (fr)
HU (1)	HUE066398T2 (fr)
IL (2)	IL271573B2 (fr)
LT (1)	LT3645551T (fr)
MA (1)	MA49513B1 (fr)
MD (1)	MD3645551T2 (fr)
MX (2)	MX2020000244A (fr)
PE (1)	PE20200488A1 (fr)
PH (1)	PH12019550266A1 (fr)
PL (1)	PL3645551T3 (fr)
PT (1)	PT3645551T (fr)
RS (1)	RS65569B1 (fr)
SG (1)	SG11201911610TA (fr)
SI (1)	SI3645551T1 (fr)
SM (1)	SMT202400189T1 (fr)
WO (1)	WO2019006043A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2018338728B2 (en)	2017-09-29	2025-01-02	Centre National De La Recherche Scientifique (Cnrs)	Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3856762A1 (fr)	2018-09-28	2021-08-04	Voyager Therapeutics, Inc.	Constructions d'expression de frataxine comprenant des promoteurs modifiés et leurs méthodes d'utilisation
CN113166208B (zh)	2018-10-02	2024-11-22	沃雅戈治疗公司	重新定向aav衣壳的嗜性
EP3736330A1 (fr) *	2019-05-08	2020-11-11	European Molecular Biology Laboratory	Particules modifiées du virus adéno-associé (aav) pour la thérapie génique
JP2022533438A (ja)	2019-05-24	2022-07-22	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	改変ウイルス粒子およびその使用
TWI900553B (zh)	2020-05-13	2025-10-11	美商航海家醫療公司	Aav蛋白殼之趨性重定向
AU2021378075B2 (en)	2020-11-11	2025-03-27	Borea Therapeutics S.R.L.	Modified viral particles for gene therapy
CN115873987A (zh) *	2021-09-30	2023-03-31	北京五加和基因科技有限公司	检测腺相关病毒载体感染滴度的方法和试剂盒
EP4426716A1 (fr)	2021-11-02	2024-09-11	Voyager Therapeutics, Inc.	Variants capsidiques de vaa et utilisations associées
JP2024540181A (ja)	2021-11-04	2024-10-31	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	骨格筋に再標的化されたウイルス粒子
CN114213505B (zh) *	2021-12-10	2022-09-20	和元生物技术（上海）股份有限公司	一种适用于特异感染u87-mg细胞的腺相关病毒突变体
CN119095866A (zh) *	2022-02-22	2024-12-06	北卡罗来纳大学查佩尔希尔分校	嵌合神经向性aav衣壳
CN115044615B (zh) *	2022-04-28	2025-09-05	三峡大学	一种靶向感染乳腺癌细胞的aav载体及应用
US20250302998A1 (en)	2022-05-09	2025-10-02	Regeneron Pharmaceuticals, Inc.	Vectors and methods for in vivo antibody production
US20250312487A1 (en) *	2022-05-13	2025-10-09	Children's Medical Research Institute	Adeno-associated virus capsids
CA3263388A1 (fr)	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Particules virales reciblées vers le récepteur 1 de transferrine
KR20250116795A (ko)	2022-11-14	2025-08-01	리제너론 파마슈티칼스 인코포레이티드	별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
EP4634220A2 (fr) *	2022-12-16	2025-10-22	Regeneron Pharmaceuticals, Inc.	Molécules de liaison à l'antigène qui se lient à des particules d'aav et utilisations
CN119894939A (zh) *	2022-12-23	2025-04-25	北京大学宁波海洋药物研究院	衣壳蛋白-抗体偶联物、修饰的病毒、药物组合和用途
EP4665764A1 (fr)	2023-02-13	2025-12-24	Regeneron Pharmaceuticals, Inc.	Traitement de troubles musculaires avec des anticorps anti-cacng1 humains
WO2024229105A1 (fr)	2023-05-02	2024-11-07	Regeneron Pharmaceuticals, Inc.	Anticorps anti-m-cadhérine humaine (cdh15), conjugués et leurs utilisations pour l'administration de charges utiles génétiques à des cellules musculaires
CN118955652A (zh) *	2023-05-15	2024-11-15	杭州新昶基因技术有限公司	腺相关病毒衣壳蛋白、包含其的腺相关病毒及应用
EP4630457A1 (fr) *	2023-08-18	2025-10-15	Regeneron Pharmaceuticals, Inc.	Molécules bispécifiques de liaison à l'antigène et leurs utilisations
WO2025072501A2 (fr) *	2023-09-26	2025-04-03	The Trustees Of Princeton University	Procédé de conversion de farnésyl pyrophosphate synthase en géranyl pyrophosphate synthase
WO2025151796A1 (fr)	2024-01-11	2025-07-17	Regeneron Pharmaceuticals, Inc.	Particules virales reciblées sur tissus du système nerveux
US20250242018A1 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184603A2 (fr)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Utilisation d'inhibiteurs de cd40 pour inhiber une réponse immunitaire et permettre une administration et une réadministration d'immunogène
WO2026025058A1 (fr)	2024-07-25	2026-01-29	Regeneron Pharmaceuticals, Inc.	Particules virales d'aav reciblées sur des cellules cancéreuses exprimant le r-egf
WO2026039325A2 (fr)	2024-08-12	2026-02-19	Regeneron Pharmaceuticals, Inc.	Gènes mtm1 modifiés et utilisations associées
CN119039401B (zh) *	2024-08-19	2025-04-11	广州派真生物技术有限公司	腺相关病毒突变体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2224907A1 (fr)	1995-07-25	1997-02-13	Introgene B.V.	Procedes et moyens d'apport cible de genes
IL137681A0 (en)	1998-02-06	2001-10-31	Uab Research Foundation	Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
DE19849643A1 (de) *	1998-10-29	2000-05-04	Deutsches Krebsforsch	An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer
DE19933719A1 (de) *	1999-07-19	2001-01-25	Medigene Ag	Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US20050233307A1 (en) *	2002-09-12	2005-10-20	Kyle Gee	Site-specific labeling of affinity tags in fusion proteins
US7273835B2 (en) *	2004-08-04	2007-09-25	Honeywell International Inc.	Azeotrope-like compositions of difluoromethane
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
ES2971647T3 (es)	2005-04-15	2024-06-06	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
EP2012122A1 (fr)	2007-07-06	2009-01-07	Medigene AG	Protéines structurelles de parvovirus muté
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
MY192182A (en)	2009-06-26	2022-08-04	Regeneron Pharma	Readily isolated bispecific antibodies with native immunoglobulin format
ES2724975T3 (es)	2009-12-10	2019-09-18	Regeneron Pharma	Ratones que producen anticuerpos de cadena pesada
FR2955773B1 (fr) *	2010-02-01	2017-05-26	Commissariat Energie Atomique	Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
US20150203591A1 (en)	2012-08-02	2015-07-23	Regeneron Pharmaceuticals, Inc.	Mutivalent antigen-binding proteins
EP3492597A3 (fr) *	2013-05-21	2019-08-28	University of Florida Research Foundation, Inc.	Compositions de vecteur aav3 recombinant à capside modifiée et procédés d'utilisation dans la thérapie génétique du cancer du foie chez l'homme
CA3124228C (fr)	2014-03-21	2024-05-14	Regeneron Pharmaceuticals, Inc.	Animaux non humains qui produisent des proteines de liaison monodomaine
US10370432B2 (en) *	2014-10-03	2019-08-06	University Of Massachusetts	Heterologous targeting peptide grafted AAVS
DE102015207516A1 (de) *	2015-04-23	2016-10-27	Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe	Kopplung von Proteinen von Interesse (POI) mit viralen Vektoren mittels Intein-vermittelten Proteinspleißens

2018
- 2018-06-27 PE PE2019002652A patent/PE20200488A1/es unknown
- 2018-06-27 KR KR1020247032850A patent/KR102877478B1/ko active Active
- 2018-06-27 SG SG11201911610TA patent/SG11201911610TA/en unknown
- 2018-06-27 FI FIEP18749635.1T patent/FI3645551T3/fi active
- 2018-06-27 MA MA49513A patent/MA49513B1/fr unknown
- 2018-06-27 PT PT187496351T patent/PT3645551T/pt unknown
- 2018-06-27 EP EP24154743.9A patent/EP4372008A3/fr active Pending
- 2018-06-27 LT LTEPPCT/US2018/039874T patent/LT3645551T/lt unknown
- 2018-06-27 MX MX2020000244A patent/MX2020000244A/es unknown
- 2018-06-27 DK DK18749635.1T patent/DK3645551T5/da active
- 2018-06-27 SI SI201831093T patent/SI3645551T1/sl unknown
- 2018-06-27 HR HRP20240773TT patent/HRP20240773T1/hr unknown
- 2018-06-27 MD MDE20200492T patent/MD3645551T2/ro unknown
- 2018-06-27 KR KR1020257035498A patent/KR20250160215A/ko active Pending
- 2018-06-27 HU HUE18749635A patent/HUE066398T2/hu unknown
- 2018-06-27 CN CN201880042990.1A patent/CN110799524A/zh active Pending
- 2018-06-27 PL PL18749635.1T patent/PL3645551T3/pl unknown
- 2018-06-27 IL IL271573A patent/IL271573B2/en unknown
- 2018-06-27 US US16/625,189 patent/US20200140491A1/en active Pending
- 2018-06-27 BR BR112019027854-0A patent/BR112019027854A2/pt active Search and Examination
- 2018-06-27 SM SM20240189T patent/SMT202400189T1/it unknown
- 2018-06-27 WO PCT/US2018/039874 patent/WO2019006043A1/fr not_active Ceased
- 2018-06-27 EP EP18749635.1A patent/EP3645551B1/fr active Active
- 2018-06-27 IL IL317938A patent/IL317938A/en unknown
- 2018-06-27 ES ES18749635T patent/ES2978295T3/es active Active
- 2018-06-27 KR KR1020207001282A patent/KR102714347B1/ko active Active
- 2018-06-27 AU AU2018290882A patent/AU2018290882B2/en active Active
- 2018-06-27 JP JP2019572024A patent/JP7372154B2/ja active Active
- 2018-06-27 RS RS20240615A patent/RS65569B1/sr unknown
- 2018-06-27 CN CN202310920054.9A patent/CN117051045B/zh active Active
- 2018-06-27 CA CA3066947A patent/CA3066947A1/fr active Pending
2019
- 2019-12-05 PH PH12019550266A patent/PH12019550266A1/en unknown
- 2019-12-24 CO CONC2019/0014683A patent/CO2019014683A2/es unknown
- 2019-12-26 CL CL2019003842A patent/CL2019003842A1/es unknown
2020
- 2020-01-08 MX MX2023009050A patent/MX2023009050A/es unknown
- 2020-12-22 CL CL2020003343A patent/CL2020003343A1/es unknown
2022
- 2022-10-11 JP JP2022163041A patent/JP7851839B2/ja active Active
2023
- 2023-07-19 AU AU2023206143A patent/AU2023206143B2/en active Active
2024
- 2024-02-08 JP JP2024017826A patent/JP2024036644A/ja active Pending
- 2024-05-07 CL CL2024001376A patent/CL2024001376A1/es unknown
2026
- 2026-01-07 JP JP2026001735A patent/JP2026042952A/ja active Pending
- 2026-01-23 AU AU2026200511A patent/AU2026200511A1/en active Pending

Also Published As

Publication number	Publication date
BR112019027854A2 (pt)	2020-07-07
MX2020000244A (es)	2020-09-28
CO2019014683A2 (es)	2020-01-17
PT3645551T (pt)	2024-05-13
JP7851839B2 (ja)	2026-04-27
KR20250160215A (ko)	2025-11-11
IL317938A (en)	2025-02-01
LT3645551T (lt)	2024-05-10
EP4372008A2 (fr)	2024-05-22
CN110799524A (zh)	2020-02-14
FI3645551T3 (fi)	2024-05-03
IL271573B1 (en)	2025-02-01
MX2023009050A (es)	2023-08-10
PH12019550266A1 (en)	2021-01-11
CA3066947A1 (fr)	2019-01-03
MD3645551T2 (ro)	2024-08-31
JP2022183228A (ja)	2022-12-08
RU2020101279A (ru)	2021-07-27
EP3645551B1 (fr)	2024-03-13
CL2020003343A1 (es)	2021-06-25
IL271573B2 (en)	2025-06-01
IL271573A (en)	2020-02-27
SMT202400189T1 (it)	2024-07-09
SI3645551T1 (sl)	2024-06-28
MA49513B1 (fr)	2024-05-31
KR102877478B1 (ko)	2025-10-29
AU2023206143A1 (en)	2023-08-10
SG11201911610TA (en)	2020-01-30
CL2024001376A1 (es)	2024-10-25
AU2026200511A1 (en)	2026-02-12
AU2018290882B2 (en)	2023-07-27
AU2023206143B2 (en)	2025-10-30
CL2019003842A1 (es)	2020-07-24
BR122023021213A2 (pt)	2024-02-20
CN117051045A (zh)	2023-11-14
RS65569B1 (sr)	2024-06-28
DK3645551T3 (da)	2024-05-06
KR102714347B1 (ko)	2024-10-14
AU2018290882A1 (en)	2020-01-16
DK3645551T5 (da)	2024-08-26
EP3645551A1 (fr)	2020-05-06
US20200140491A1 (en)	2020-05-07
PE20200488A1 (es)	2020-03-03
RU2020101279A3 (fr)	2022-02-04
JP2026042952A (ja)	2026-03-11
ES2978295T3 (es)	2024-09-10
WO2019006043A1 (fr)	2019-01-03
JP2024036644A (ja)	2024-03-15
HRP20240773T1 (hr)	2024-09-13
KR20240149451A (ko)	2024-10-14
PL3645551T3 (pl)	2024-07-01
EP4372008A3 (fr)	2024-07-31
KR20200022434A (ko)	2020-03-03
JP7372154B2 (ja)	2023-10-31
HUE066398T2 (hu)	2024-07-28
JP2020529196A (ja)	2020-10-08
CN117051045B (zh)	2025-04-08

Publication	Publication Date	Title
MA49513A (fr)	2020-05-06	Vecteurs viraux recombinés à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines
MA49514A (fr)	2020-05-06	Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines
EP3635108A4 (fr)	2021-03-31	Agents d'activation destinés à la transfection de cellules et/ou la production de vecteur raav améliorées
EP3845654A4 (fr)	2022-05-11	Cellules t exprimant-car et vecteur d'expression car
EP3728568A4 (fr)	2021-10-06	Procédés et compositions pour l'administration de vecteurs viraux à travers la barrière hémato-encéphalique
EP3883585A4 (fr)	2022-12-14	Agent thérapeutique d'expression de cellules modifiées et utilisations associées
EP3642353A4 (fr)	2021-02-24	Évaluation du risque de complication d'une greffe avec l'adn acellulaire total
EP3414787A4 (fr)	2019-06-19	Matériaux d'électrode prélithiés et cellules les comprenant
IL290132A (en)	2022-03-01	Materials and methods for treating friedreich's ataxia
EP3443081A4 (fr)	2019-10-30	Répresseurs à base de crispr/cas9 pour inactiver des cibles géniques in vivo et procédés d'utilisation
EP3390643A4 (fr)	2019-08-28	Constructions plasmidiques pour l'expression de protéines hétérologues et leurs procédés d'utilisation
EP3604524A4 (fr)	2020-04-29	Nouvelle technique de clonage direct de grands fragments génomiques et ensemble multi-moléculaire d'adn
MA55313A (fr)	2022-01-19	Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii
EP3835418A4 (fr)	2022-05-04	Nouvelle protéine associée aux crispr et utilisation de celle-ci
EP3506917A4 (fr)	2020-05-06	Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci
EP3413887A4 (fr)	2019-08-14	Intermédiaires utilisés dans la synthèse d'éribuline et procédés de synthèse associés
EP3880827A4 (fr)	2023-04-26	Compositions et procédés pour induire la différenciation d'une cellule capillaire
EP3724883A4 (fr)	2021-09-01	Détection de délétions et de variations de nombre de copies dans des séquences d'adn
HUE062806T2 (hu)	2023-12-28	Vektorok Friedreich-ataxia kezelésére
EP3601572A4 (fr)	2021-01-06	Construction d'expression de protéine et procédés associés
EP3455360A4 (fr)	2019-12-04	Constructions d'adn pour la fabrication de polypeptides biothérapeutiques pour utilisation dans des vaccins et des agents thérapeutiques pour animaux
EP3870705A4 (fr)	2022-07-27	Amélioration de la qualité d'adn acellulaire
EP3454913A4 (fr)	2019-11-27	Conjugué thérapeutique de ciblage osseux et méthodes de fabrication et d'utilisation de celui-ci
EP3679050A4 (fr)	2021-06-16	Procédés et compositions destinés à l'expression améliorée de protéines recombinantes
EP3934892A4 (fr)	2022-10-05	Réduction de l'agglomération d'une matière de fabrication